title: Reactivation of Epstein-Barr virus in B cells of patients with chronic hepatitis C.
abstract: Hepatitis C virus (HCV) infection is associated with lymphoproliferative disorders. HCV infection of B cells is a predictive factor for lymphoproliferative disorders in patients with chronic hepatitis C, although its molecular mechanisms remain unknown. Epstein-Barr virus (EBV) is a B cell-tropic virus with the potential to cause lymphoproliferative disorders, and its reactivation is induced by several viruses and cytokines. The possibility that HCV infection triggers reactivation of EBV and induces lymphoproliferative disorders were investigated. Expression of EBV mRNAs was analyzed by RT-PCR in patients infected with HCV and control subjects, and correlations between reactivation of EBV and markers for lymphoproliferative disorders were investigated. BZLF1 mRNA, a starter molecule of reactivation, was detected in peripheral blood mononuclear cells from 12 of 52 (23%), patients infected with HCV and the frequency was higher than in healthy subjects [3 of 43 (9%), P = 0.032]. But the presence of the BZLF1 mRNA was not associated with an abnormality of markers for lymphoproliferative disorders. This study on BZLF1 mRNA expression among lymphoid cell subsets showed that reactivation of EBV was observed specifically in B cells. The BZLF1 mRNA disappeared following anti-viral therapy and remained negative after eradication of HCV in patients with a sustained viral response, while the EBER1 RNA, a marker for persistence of EBV, was detected throughout the therapy. Infection with HCV induces reactivation of EBV in B cells, but this reactivation was not associated directly with lymphoproliferative disorders triggered by HCV.
authors.affiliation: Division of Gastroenterology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.
authors.forename: Yuu
authors.initials: Y
authors.lastname: Shimozuma
authors.forename: Takayoshi
authors.initials: T
authors.lastname: Ito
authors.forename: Momoko
authors.initials: M
authors.lastname: Inokuchi
authors.forename: Manabu
authors.initials: M
authors.lastname: Uchikoshi
authors.forename: Miyuki
authors.initials: M
authors.lastname: Miyashita
authors.forename: Hisako
authors.initials: H
authors.lastname: Nozawa
authors.forename: Tomoe
authors.initials: T
authors.lastname: Shimazaki
authors.forename: Kazumasa
authors.initials: K
authors.lastname: Hiroishi
authors.forename: Michio
authors.initials: M
authors.lastname: Imawari
mesh_terms: D000328:Adult; D000368:Aged; D001402:B-Lymphocytes / Q000821:virology*; D020031:Epstein-Barr Virus Infections / Q000150:complications* / Q000821:virology; D005260:Female; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000821:virology; D004854:Herpesvirus 4, Human / Q000235:genetics / Q000378:metabolism / Q000502:physiology*; D006801:Humans; D008232:Lymphoproliferative Disorders / Q000821:virology*; D008297:Male; D008875:Middle Aged; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D012367:RNA, Viral / Q000235:genetics / Q000378:metabolism; D015534:Trans-Activators / Q000235:genetics / Q000378:metabolism; D014775:Virus Activation
chemical_list: C063676:BZLF1 protein, Herpesvirus 4, Human; D012333:RNA, Messenger; D012367:RNA, Viral; D015534:Trans-Activators